Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma
| Autor: | Masaya Okura, Mitomu Kioi, Tadaaki Kirita, Takahiko Shibahara, Souichi Yanamoto, Narikazu Uzawa, Hideki Tanzawa, Yoshihide Ota, Jingo Kusukawa, Tetsuro Yamashita, Masahiro Umeda, Hiroyuki Hamakawa, Satoshi Yokoo, Hiroyoshi Hiratsuka, Iwai Tohnai, Hiroshi Kurita |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty medicine.medical_treatment Cetuximab Kaplan-Meier Estimate Toxicology Gastroenterology Drug Administration Schedule Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Neoplasm Metastasis Adverse effect Aged Aged 80 and over Pharmacology Cisplatin Chemotherapy Leukopenia business.industry Retrospective cohort study Exanthema Middle Aged Rash Treatment Outcome 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Mouth Neoplasms Fluorouracil Neoplasm Recurrence Local medicine.symptom business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 81:549-554 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-018-3531-x |
| Popis: | The purpose of this study was to assess the efficacy and safety of cetuximab plus platinum-based chemotherapy for patients specifically diagnosed with recurrent or metastatic oral squamous cell carcinoma (OSCC). We conducted a multicenter retrospective observational study of patients who underwent first-line cetuximab plus platinum-based chemotherapy between December 2012 and June 2015. 65 patients received weekly cetuximab (week 1, 400 mg/m2; subsequent weeks, 250 mg/m2) plus a maximum of six 3-weekly cycles of cisplatin (80 or 100 mg/m2, day 1) or carboplatin (at an area under the curve of 5 mg/mL/min as a 1-h intravenous infusion on day 1) and 5-fluorouracil (800 or 1000 mg/m2/day, days 1–4). Patients with stable disease who received cetuximab plus platinum-based chemotherapy continued to receive cetuximab until disease progression or unacceptable toxicities, whichever occurred first. The median follow-up was 10.5 (range 1.2–34.2) months. The best overall response and the disease control rates were 46.2 and 67.7%, respectively. The median overall survival and progression-free survival rates were 12.1 and 7.8 months, respectively. The most common grades 3–4 adverse events were skin rash (9.2%) followed by leukopenia (6.2%). None of the adverse events were fatal. The results of our multicenter retrospective study, which was the largest of its kind to date, suggest that first-line cetuximab plus platinum-based chemotherapy is suitable and well-tolerated for the systemic therapy of recurrent or metastatic OSCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink